Skip to main content

HELP · Helus Pharma Inc.

Track HELP — free
$6.74 -0.04 (-0.53%)
Market Cap
$541.16M
Shares
79.82M
Volume · Nov 19 2.06M Avg daily vol (3M) 1.83M

Price & Indicators

 

Key stats

Close
$6.78
Open
$7.00
Day range
$6.51–7.14
52-week closing range
$3.87–14.02
Average volume, 30 days
2.0M
Short interest
2.7M · 3.3% of shares · 2.1 days
Short volume, last session
37%
Last earnings
Nov 16, 2026
Price history
Mar 2020 to Nov 2026

Up next

Sep 10, 2027 Est · unconfirmed · in 42 wks

Latest documents

2026
Nov 16
Current report 6-K
HLP003 achieves rapid, durable Phase 3 depression improvements

Helus Pharma reported positive Phase 3 APPROACH results for HLP003 in adults with major depressive disorder: placebo-adjusted MADRS reductions of -7.6 points at Week 6 and -7.0 points at Week 12, each p<0.0001.

3 source passages
Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: HELP) (“Helus Pharma” or the “Company”), a clinical-stage pharmaceutical company committed to improving the treatment landscape in mental health conditions through the development and commercialization of novel serotonergic agonists (“NSAs”), today announced positive topline results from APPROACH, its Phase 3 pivotal study evaluating HLP003 (deuterated psilocin), as an adjunctive treatment for adults with major depressive disorder (“MDD”). At the primary endpoint of 6 weeks, the least squares (“LS”) mean reduction from baseline in the MADRS total score for HLP003 was 19.5 points versus 11.9 points for placebo (LS mean difference = -7.6 points, p<0.0001, effect size=0.653). This effect was durable with an LS mean reduction from baseline in the MADRS total score for HLP003 of 16.9 points versus 9.9 points for placebo (LS mean difference = -7.0 points, p<0.0001, effect size=0.581) at the key secondary endpoint of 12 weeks. Open the document at this passage
Nov 16
Current report 6-K
APPROACH enrollment complete; Q4 2026 topline data on track

Helus Pharma completed enrollment in Phase 3 APPROACH for HLP003 in MDD, with topline data on track for Q4 2026. Cash totaled $171.1 million and net loss was $103.1 million for the quarter ended September 30, 2026.

4 source passages
During the quarter, Helus Pharma completed enrollment in APPROACH, its Phase 3 pivotal study evaluating HLP003 as an adjunctive treatment in MDD. APPROACH has completed enrollment, and the study is on track for topline data readout in Q4 2026.1,2 Cash totaled $171.1 million as of September 30, 2026. Net loss was $103.1 million for the quarter ended September 30, 2026, compared to a net loss of $33.7 million in the same period last year. Open the document at this passage
Nov 16
Current report 6-K
Phase 3 HLP003 topline results webcast scheduled

Helus Pharma Inc. will present topline results from its Phase 3 APPROACH study evaluating HLP003 in major depressive disorder during a webcast at 8:00 a.m. EDT on November 16, 2026.

2 source passages
Helus Pharma to Present Topline Results from Phase 3 APPROACH Study Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026 Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: HELP) (the "Company" or "Helus Pharma"), a clinical-stage pharmaceutical company committed to improving the treatment landscape in mental health through the development and commercialization of novel serotonergic agonists ("NSAs"), today announced that it will host a webcast tomorrow at 8:00 a.m. EDT to present topline results from its Phase 3 APPROACH study evaluating HLP003 in major depressive disorder ("MDD"). Open the document at this passage
Nov 13
Current report 6-K
Six-month loss reached $150,910 thousand; cash $171,071 thousand

Helus Pharma Inc. reported a six-month net loss of $150,910 thousand for the period ended September 30, 2026, versus $58,335 thousand in 2025, while cash reached $171,071 thousand at September 30, 2026.

Read from the first part of this long document
6 source passages
HELUS PHARMA INC. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS (All amounts expressed in thousands of United States dollars, except share and per share amounts) (Unaudited) For the three months ended September 30, | | For the six months ended September 30, | | | | 2026 | 2025 | 2026 | 2025 NET LOSS FOR THE PERIOD | | (103,091) | (33,722) | (150,910) | (58,335) CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (All amounts expressed in thousands of United States dollars) (Unaudited) As at | | September 30, 2026 | March 31, 2026 | | | Notes | $ | $ | ASSETS | | | | Current | | | | Cash | | 171,071 | 157,258 Open the document at this passage
Nov 9
Investor event
OO3 phase three readout expected later this quarter

Healus Pharma expects an OO3 phase three major depressive disorder readout later this quarter, plans a 2028 NDA filing and approval, and reported approximately $165 million on its balance sheet.

4 source passages
I'm always excited to be here talking about Healus Pharma. Our OO3 program is deuterated psilocin for the adjunctive treatment of major depressive disorder. That's in phase three. We have an upcoming readout of our first phase three trial anticipated later this quarter. We have breakthrough therapy designation for the program, for the molecule, and so that would expect a rolling submission there. So also would anticipate approval in 2028 as well, but have the full standard program to support that. I think the last financials we filed, approximately $165 million on the balance sheet Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+8.0%
Year over year · more shares
Price change (1Y)
+14.3%
Trailing year
Short interest
3.3%
Latest settlement · 2.1 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Neutral Sentiment Very Bullish Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −13%
below
Price vs 50-day avg −37%
below
RSI (14) 27
oversold
MACD trend Negative
52-week position 29%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Neutral
1-month return −35%
trailing
6-month return +45%
trailing
YTD return −17%
this year
Relative strength +50%
vs S&P · 6-mo
Sentiment
smart money
Very Bullish
Trend (MA cross) No cross
50d $11 › 200d $8 — 50d above 200d
Institutional flow Accumulating
+10% holders QoQ · +36 funds added
Insider flow Accumulating
Net +$9.7M over 90 days · 0% sells
Short interest Falling
3.34% of shares out · ▼ -11.5% MoM · 2.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
110 holders — near 2-yr high, broad support
Squeeze score 47
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 88%
annualized · 1-yr
Max drawdown −56%
past year
ATR 13.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−13% Bearish
Price vs 50-day avg
−37% Bearish
RSI (14)
27 Neutral
MACD trend
Negative Bearish
52-week position
29% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 4 of 6
Trend (MA cross) No cross
50d $11 › 200d $8 — 50d above 200d
Institutional flow Accumulating
+10% holders QoQ · +36 funds added
Insider flow Accumulating
Net +$9.7M over 90 days · 0% sells
Short interest Falling
3.34% of shares out · ▼ -11.5% MoM · 2.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
110 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $4 Now $7 · 29% Range high $14
vs 200-day avg -13% vs 50-day avg -37%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
HELP
Helus Pharma Inc.
this stock
$541.16M -17.1% — — 3.3%
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.36B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
110
% held
33.4%
Net QoQ
-3.2M sh
Top holder
ADAGE CAPITAL PARTNERS GP…
Held Float
View
Held by Funds
Fund positions
6
View
Short & Settlement
Short Interest Falling
Shares short
2.7M
Days to cover
2.1d
Change
-345.7K sh
View
Short Volume
Short vol %
37%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
900
Value
$9.6K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
47.4%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Cluster buy
Net (90d)
+$9.7M
Buyers / Sellers
4 / 0
Buyers Sellers
View
Filings
SEC Filings
Latest
6-K
Filed
Nov 16, 2026
This year
56

Helus Pharma reported positive Phase 3 APPROACH results for HLP003 in adults with major depressive disorder: placebo-adjusted MADRS reductions of -7.6 points at Week 6 and -7.0 points at Week 12, each p<0.0001.

View
Exempt Offerings
Offering
$262.0K
Filed
Sep 1, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 16, 2026
View

Performance

5D 20D 120D MTD YTD
HELP -23.5% -35.4% +44.6% -36.0% -17.1%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -18.0% -29.1% +50.2% -30.7% -22.1%
Key facts CIK 1833141 CUSIP 423492107 13F (30d) 103 filings 101 filers Visit website Investor relations